Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India. (July 2021)

• Record Type: Journal Article
• Authors: Patil, Amol Prabhakar; Simon, Ebby George; Dutta, Amit Kumar; Joseph, Anjilivelil Joseph; Kurien, Reuben Thomas; Chowdhury, Sudipta Dhar
• Is Part Of: Tropical doctor. Volume 51:Number 3(2021)
• Page Start: 326
• Page End: 331
• Publication Date: 2021-07
• Subjects: Inflammatory bowel disease -- hepatitis B -- serology -- vaccination; Tropical medicine -- Periodicals; Medical care -- Developing countries -- Periodicals; Developing Countries -- Periodicals; Tropical Medicine -- Periodicals; Tropische geneeskunde; 616.9883
• DOI: 10.1177/00494755211015571
• Languages: English
• ISSNs: 0049-4755

Abstract

Inflammatory bowel disease patients are at risk of hepatitis B infection. Data on this prevalence from South Asia are limited. We conducted a prospective study comprising of 76 inflammatory bowel disease patients between October 2013 and August 2014. Prevalence of hepatitis B surface antigen in inflammatory bowel disease, ulcerative colitis and Crohn's disease patients were 2.6%, 2.4% and 3% respectively and that of markers of hepatitis B exposure (hepatitis B surface antigen /hepatitis B core antibody) were 11.8%, 14.3% and 9.1% respectively. Risk factors found significantly more common in those positive for viral markers compared to those negative were age, non-inflammatory bowel disease related surgery and hospital admission. Only 7(9.2%) had completed hepatitis B vaccination. There is a need to create awareness among physicians regarding the importance of hepatitis B screening and vaccination in inflammatory bowel disease patients.